{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T15:44:15Z","timestamp":1700581455896},"reference-count":32,"publisher":"Walter de Gruyter GmbH","issue":"2","license":[{"start":{"date-parts":[[2012,1,1]],"date-time":"2012-01-01T00:00:00Z","timestamp":1325376000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Proprotein convertase subtilisin\/kexin type 9 (PCSK9) has emerged as a novel target for controlling plasma levels of low-density lipoprotein cholesterol (LDL-C) and decreasing the risk of cardiovascular diseases. At present it is clear that the major classes of commonly prescribed lipid-lowering medications increase serum PCSK9 levels and fail to protect a significant percentage of patients from cardiovascular events. Therefore development of new LDL-C lowering medications that either do not increase circulating PCSK9 levels or work through inhibition of PCSK9 expression and protease activity is a highly desirable approach to overcome hypercholesterolemia. Since there are several agents which are being evaluated in human preclinical and clinical trials, this review summarizes current therapeutic strategies targeting PCSK9, including specific antibodies, antisense oligonucleotides, small interfering RNAs (siRNAs) and other small-molecule inhibitors.<\/jats:p>","DOI":"10.2478\/s11658-012-0006-7","type":"journal-article","created":{"date-parts":[[2012,2,7]],"date-time":"2012-02-07T03:37:21Z","timestamp":1328585841000},"source":"Crossref","is-referenced-by-count":1,"title":["Proprotein convertase subtilisin\/kexin type 9: A new target molecule for gene therapy"],"prefix":"10.2478","volume":"17","author":[{"given":"Anna","family":"Banaszewska","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michal","family":"Piechota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Plewa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","reference":[{"key":"ref61","first-page":"231","article-title":"Statin use in the treatment of metabolic patient","volume":"7","author":"Koz\u0142owski","year":"2008","journal-title":"Geriatria"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1056\/NEJMoa054013","article-title":"Sequence variations in PCSK low LDL , and protection against coronary heart disease http dx doi org","volume":"2","author":"Cohen","year":"2006","journal-title":"Engl J Med"},{"key":"ref261","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.bbrc.2008.07.106","article-title":"PCSK binds to multiple receptors and can be functionally inhibited by an EGF - A peptide http dx doi org","volume":"27","author":"Shan","year":"2008","journal-title":"Biochem Biophys Res Commun"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1161\/ATVBAHA.109.194191","article-title":"PCSK dominant negative mutant results in increased LDL catabolic rate and familial hypobetalipoproteinemia Arterioscler http dx doi org","volume":"6","author":"Cariou","year":"2009","journal-title":"Thromb Vasc Biol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1086\/507488","article-title":"Molecular characterization of loss - of - function mutations in PCSK and identification of a compound heterozygote Am http dx doi org","volume":"4","author":"Zhao","year":"2006","journal-title":"Hum Genet"},{"key":"ref201","first-page":"163","article-title":"Statins and ezetimibe modulate plasma proprotein convertase subtilisin kexin - levels","volume":"21","author":"Davignon","year":"2009","journal-title":"Trans Am Clin Climatol Assoc"},{"key":"ref191","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1194\/jlr.M900273-JLR200","article-title":"A new method for measurement of total plasma PCSK : clinical applications http dx doi org","volume":"20","author":"Dubuc","year":"2010","journal-title":"Lipid Res"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"5374","DOI":"10.1073\/pnas.0501652102","article-title":"Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk http dx doi org","volume":"3","author":"Rashid","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref111","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.amjcard.2004.10.012","article-title":"Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia ( the SAFARI trial ) http dx doi org","volume":"12","author":"Grundy","year":"2005","journal-title":"Am J Cardiol"},{"key":"ref01","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/ng1161","article-title":"Mutations in PCSK cause autosomal dominant hypercholesterolemia http dx doi org","volume":"1","author":"Abifadel","year":"2003","journal-title":"Nat Genet"},{"key":"ref121","doi-asserted-by":"publisher","first-page":"121","DOI":"10.2165\/00003495-200767010-00013","article-title":"Fenofibrate A review of its use in primary dyslipidemia , the metabolic syndrome and type diabetes mellitus http dx doi org","volume":"13","author":"Keating","year":"2007","journal-title":"Drugs"},{"key":"ref281","doi-asserted-by":"publisher","first-page":"9820","DOI":"10.1073\/pnas.0903849106","article-title":"A proprotein convertase subtilisin \/ kexin type neutralizing antibody reduces serum cholesterol in mice and nonhuman primates http dx doi org","volume":"29","author":"Chan","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref151","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1194\/jlr.M000620","article-title":"Fenofibrate treatment increases human serum proprotein convertase subtilisin kexin type levels http dx doi org","volume":"16","author":"Troutt","year":"2010","journal-title":"Lipid Res"},{"key":"ref71","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1161\/01.ATV.0000134621.14315.43","article-title":"Statins upregulate PCSK the gene encoding the proprotein convertase neural apoptosis - regulated convertase - implicated in familial hypercholesterolemia Arterioscler http dx doi org","volume":"8","author":"Dubuc","year":"2004","journal-title":"Thromb Vasc Biol"},{"key":"ref131","doi-asserted-by":"publisher","first-page":"9666","DOI":"10.1074\/jbc.M705831200","article-title":"Dual mechanisms for the fibrate - mediated repression of proprotein convertase subtilisin \/ kexin type http dx doi org","volume":"14","author":"Kourimate","year":"2008","journal-title":"Biol Chem"},{"key":"ref371","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/nrm1129","article-title":"Killing the messenger : short RNAs that silence gene expression http dx doi org","volume":"38","author":"Dykxhoorn","year":"2003","journal-title":"Nat Rev Mol Cell Biol"},{"key":"ref141","doi-asserted-by":"publisher","first-page":"4985","DOI":"10.1210\/en.2006-0098","article-title":"Fasting induces hyperlipidemia in mice overexpressing PCSK : Lack of modulation of VLDL hepatic output by the LDLr http dx doi org","volume":"15","author":"Lambert","year":"2006","journal-title":"Endocrinology"},{"key":"ref211","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1194\/jlr.M013664","article-title":"Improved efficacy for ezetimibe and rosuvastatin by attenuating the induction of PCSK http dx doi org","volume":"22","author":"Ason","year":"2011","journal-title":"Lipid Res"},{"key":"ref251","doi-asserted-by":"publisher","first-page":"28885","DOI":"10.1074\/jbc.M109.052407","article-title":"Hepatocyte nuclear factor alpha plays a critical role in PCSK gene transcription and regulation by the natural hypocholesterolemic compound berberine http dx doi org","volume":"26","author":"Li","year":"2009","journal-title":"Biol Chem"},{"key":"ref91","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.atherosclerosis.2010.05.027","article-title":"Plasma PCSK is increased by fenofibrate and atorvastatin in a non - additive fashion in diabetic patients http dx doi org","volume":"10","author":"Costet","year":"2010","journal-title":"Atherosclerosis"},{"key":"ref101","article-title":"High - dose atorvastatin causes a rapid sustained increase in human serum PCSK and disrupts its correlation with LDL cholesterol","volume":"11","author":"Welder","year":"2010","journal-title":"Lipid Res"},{"key":"ref81","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1194\/jlr.M700437-JLR200","article-title":"Atorvastatin increases human serum levels of proprotein convertase subtilisin \/ kexin type http dx doi org","volume":"9","author":"Careskey","year":"2008","journal-title":"Lipid Res"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/j.atherosclerosis.2006.08.039","article-title":"The mutation in PCSK is present and lowers blood cholesterol in a Southern African population http dx doi org","volume":"5","author":"Hooper","year":"2007","journal-title":"Atherosclerosis"},{"key":"ref241","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.atherosclerosis.2008.02.004","article-title":"Berberine decreases PCSK expression in HepG cells http dx doi org","volume":"25","author":"Cameron","year":"2008","journal-title":"Atherosclerosis"},{"key":"ref181","first-page":"2352","article-title":"Pharmacology and therapeutics of ezetimibe a cholesterol - absorption inhibitor http dx doi org","volume":"19","author":"Jeu","year":"2003","journal-title":"Clin Ther"},{"key":"ref161","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1373\/clinchem.2007.099747","article-title":"N Plasma PCSK concentrations correlate with LDL and total cholesterol in diabetic patients and are decreased by fenofibrate treatment http dx doi org","volume":"17","author":"Lambert","year":"2008","journal-title":"Clin Chem"},{"key":"ref231","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1038\/nm1135","article-title":"Berberine is a novel cholesterol - lowering drug working through a unique mechanism distinct from statins http dx doi org","volume":"24","author":"Kong","year":"2004","journal-title":"Nat Med"},{"key":"ref271","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1194\/jlr.M011445","article-title":"A - binding antibody that structurally mimics the EGF domain of LDL - receptor reduces LDL cholesterol in vivo http dx doi org","volume":"28","author":"Ni","year":"2011","journal-title":"Lipid Res"},{"key":"ref221","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.atherosclerosis.2007.09.034","article-title":"Effects of ezetimibe and \/ or simvastatin on LDL receptor protein expression and on LDL receptor and HMG - CoA reductase gene expression : a randomized trial in healthy men http dx doi org","volume":"23","author":"Gouni","year":"2008","journal-title":"Atherosclerosis"},{"key":"ref381","doi-asserted-by":"publisher","first-page":"11915","DOI":"10.1073\/pnas.0805434105","article-title":"Therapeutic RNAi targeting PCSK acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates http dx doi org","volume":"39","author":"Frank","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref171","first-page":"7","article-title":"Plasma PCSK levels are significantly modified by statins and fibrates in humans","volume":"18","author":"Mayne","year":"2008","journal-title":"Lipids Health Dis"},{"key":"ref331","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1194\/jlr.C600025-JLR200","article-title":"Antisense inhibition of proprotein convertase subtilisin \/ kexin type reduces serum LDL in hyperlipidemic mice http dx doi org","volume":"34","author":"Graham","year":"2007","journal-title":"Lipid Res"}],"container-title":["Cellular and Molecular Biology Letters"],"original-title":[],"link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.2478\/s11658-012-0006-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.2478\/s11658-012-0006-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.2478\/s11658-012-0006-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,4]],"date-time":"2021-03-04T05:16:31Z","timestamp":1614834991000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.2478\/s11658-012-0006-7\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1,1]]},"references-count":32,"journal-issue":{"issue":"2"},"URL":"https:\/\/doi.org\/10.2478\/s11658-012-0006-7","relation":{},"ISSN":["1689-1392"],"issn-type":[{"value":"1689-1392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,1,1]]}}}